Merck KGaA · XETR:MRK

Merck KGaA — Merck KGaA, Darmstadt, Germany — Non-Deal Roadshow (January 2025)

100 slides from Merck KGaA's roadshow presentation, January 2025

  1. Slide 1: Q3 24 Roadshow

    Merck KGaA, Darmstadt, Germany Q3 24 Roadshow Investor Relations January 2025

  2. Slide 2: Disclaimer

    Disclaimer Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials). To reflect such fact and to avoid any mis

  3. Slide 3: Vibrant Science and Technology Company

    Group is a VIBRANT SCIENCE AND TECHNOLOGY COMPANY Life Science Diversified industry leader Healthcare Global specialty innovator Electronics Ecosystem relevant portfolio Sustainability / ESG Innovating to elevate humanity 3 Updated October 2024

  4. Slide 4: Ready for compelling structural growth

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Ready for compelling structural growth Reacceleration of value compounding building on distinct and highly attractive end-market trends Multiple near-term catalysts to fuel growth uptake Life Science and Semiconductor Solutions as

  5. Slide 5: Three sectors focusing on highly innovative end-markets

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Three sectors focusing on highly innovative end-markets Life Science Healthcare Electronics Diversified industry Global specialty Ecosystem relevant leader innovator portfolio Process Solutions Oncology Semiconductor Solutions Lea

  6. Slide 6: Added scale and strengthened attractiveness of portfolio

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Added scale and strengthened attractiveness of portfolio Long-term growth trajectory Inorganic volume4 70% 25 Acquisition of Acquisition of Serono (2007) Versum Materials 22 65% Divesture of Divestment of Consumer Health 21 Generi

  7. Slide 7: Proven track record as a Value Compounder

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Company has a proven track record as a Value Compounder Compounding Growth over 15 years Demonstrating the critical ingredients for Value Compounding Innovation and leadership driven Organic growth 8% from Science & Technology inn

  8. Slide 8: Reacceleration of value compounding

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Reacceleration of value compounding Track record1 FY23 Mid Term Organic Growth 5% -2% CAGR CAGR restoring growth rate Expand EBITDA pre ~28% 28% margin margin margin upside Accelerating EPS growth and Strong FCF ~14% 10% returns m

  9. Slide 9: Poised to reach new sales heights beyond 2024

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Poised to reach new sales heights beyond 2024 Life Science drives org. sales growth in post-COVID world 1 • Majority of bioprocessing customers have reached target inventory levels in 2024 Share of net sales1 44% • Order intake in

  10. Slide 10: Attractive growth ambitions

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Attractive growth ambitions 7-9% mid-term CAGR  Market returns to +5-7% growth, China at muted level, but with above average growth mid term Life Science  Focus on growth engines, building critical mass in attractive areas, diff

  11. Slide 11: Innovating to spark future growth across the Group

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Innovating to spark future growth across the Group Future Innovations (long term) Tomorrow’s Growth Aligned to customer tech roadmaps and unmet patient needs: (Mid- to long term) • Fully autonomous process for the Todays Business

  12. Slide 12: Optimized capital allocation through distinct portfolio roles

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Optimized capital allocation through distinct portfolio roles Roles determined by thorough analysis of Investment focus on businesses with greatest markets and competitive positions strengths and attractive opportunities Competiti

  13. Slide 13: Plan delivered - ready for lower capital intensity

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Plan delivered - ready for a new phase of lower capital intensity Enhanced global footprint in place by end of 2025… 8-9% 6-7% 5-6% ~4% 2009-2015 2016-2019 2020-2022 2023-20241 Mid-term Capex to Sales % LS Site HC Site EL Site … l

  14. Slide 14: Driving enhanced FCF conversion

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Driving enhanced FCF conversion FCF as % of sales EBITDA pre margin expansion to improve with ~14% higher capacity utilization ~13% ~10% Drive incremental gains from process improvements 2009-2019 2020-2023 2023 Mid-term Digitaliz

  15. Slide 15: Track record in fast deleveraging

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Track record in fast deleveraging enabled by high-quality cash flow 4.0 • Resilient sources of cash, especially PS, SLS and Established Portfolio (HC) 3.5 • Solid investment grade ratings: Moody’s (A3) 2.8 since 2021, S&P (A) sinc

  16. Slide 16: Rigorous application of the Group M&A playbook

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Rigorous application of the Group M&A playbook Clear Financial criteria Financial Framework 1 2  M&A supports profitable growth strategy,  Strong financial capacity leveraging customer and market insights  Patient deal originat

  17. Slide 17: Leveraging growth in the attractive Life Science market

    Life Group Healthcare Electronics ESG Guidance Appendix Science Life Science Leveraging growth in the attractive Life Science market End Market Growth Positioned for Key Megatrends Leadership, Innovation and Growth Capturing growth Confirming 5-7%1 along the molecule Mid-term growth aspiration of Li

  18. Slide 18: Above market mid-term growth outlook

    Life Group Healthcare Electronics ESG Guidance Appendix Science Above market mid-term growth outlook on business mix, portfolio Process Solutions Diversifiedindustry Diversified Diversified industry industry 7 to 9% • Strengthening our leading portfolio in leader leader leader CAGR normalizing marke

  19. Slide 19: Mid-term growth outlooks remain favorable across segments

    Life Group Healthcare Electronics ESG Guidance Appendix Science Market Mid-term growth outlooks remain favorable across segments Life Science Market 1 2024: ~€220 bn, mid-term CAGR 5 to 7% Market segment Customer Geography (growth across all dimensions) Pharma largest (high 1-digit growth) China fas

  20. Slide 20: Organizational structure provides customer and portfolio focus

    Life Group Healthcare Electronics ESG Guidance Appendix Science Business Sector Overview Organizational structure provides customer and portfolio focus Process Solutions (PS) Life Science Services (LSS) Science & Lab Solutions (SLS) Best in class technologies for Focused service provider for innovat

  21. Slide 21: Process Solutions - Overview

    Life Group Healthcare Electronics ESG Guidance Appendix Science Process Solutions - Overview Comprehensive product portfolio and diversified customer base One PS portfolio Snapshot Addressing full value chain from upstream to drug product Business in numbers1 Process Solutions >10,000 ~3,000 SU, Sys

  22. Slide 22: Portfolio very comprehensive across equipment, consumables, raw materials

    Life Group Healthcare Electronics ESG Guidance Appendix Science Process Solutions Portfolio very comprehensive across equipment, consumables, raw materials Market segment Positioning Process  Process Solutions is strongly positioned Solutions with comprehensive holistic offering  Each player with

  23. Slide 23: Building focused end to end multimodality CDMO/CTO business

    Life Group Healthcare Electronics ESG Guidance Appendix Science Life Science Services Building focused end to end multimodality CDMO/CTO business Strategic Highlights focus Innovating for Shaping testing ▪ Leading player with regulatory/ Sustainability speed & quality paradigm technical expertise &

  24. Slide 24: Capturing durable growth across diverse market segments

    Life Group Healthcare Electronics ESG Guidance Appendix Science Science & Lab Solutions Capturing durable growth across diverse market segments ▪ Future-proofing established podium Innovation Sustainability Digitization positions Portfolio • Photo-catalysis solns. • Green chemistry • Tech. bricks fo

  25. Slide 25: All business units contributing to attractive mid-term outlook

    Life Group Healthcare Electronics ESG Guidance Appendix Science Outlook All business units contributing to attractive mid-term outlook 1 Sales split Mid-term outlook Key differentiators • Innovation leadership: factory of the future (BioContinuumTM), templates for novels, Group’s antibody developmen

  26. Slide 26: Committed to innovation, building on resilient portfolio

    Life Group Healthcare Electronics ESG Guidance Appendix Science Healthcare Committed to innovation, building on top of a resilient portfolio End Market Growth Positioned for Key Megatrends Leadership, Innovation and Growth Global Pharma Oncology and N&I Slight sales CAGR mid-term, Industry to at the

  27. Slide 27: Resilient product portfolio as base for LT growth

    Life Group Healthcare Electronics ESG Guidance Appendix Science Healthcare Resilient product portfolio as base for attractive LT growth potential Healthcare sales, illustrational graph applying CAGR based growth rates MSD growth slight growth Innovative Franchises Future growth drivers incl. pimicot

  28. Slide 28: Established Franchises – CM&E

    Life Group Healthcare Electronics ESG Guidance Appendix Science Established Franchises – CM&E Diversified leadership positions, growth driven by developing markets CM&E Sales €2.8bn in FY 2023 (~4% CAGR ’18-23)6 Position Sales by Core Brands in m€6 Value Market CAGR mid-term Markets: Mature Developi

  29. Slide 29: Established Franchises - Fertility

    Life Group Healthcare Electronics ESG Guidance Appendix Science Established Franchises - Fertility Expanding on our leadership position Global Gonadotropin market in € bn1 world’s most prescribed r-hFSH treatment2 +11% , the only recomb. FSH+LH product in the market 3.5 46% 3.0 3.0 Complemented by a

  30. Slide 30: Innovative Franchises – Commercialized assets

    CM&E Life Group Healthcare Electronics ESG Guidance Appendix Science Innovative Franchises – Commercialized assets Competitive pressures moderated by Erbitux + staggered Mavenclad LOE mCRC, SCCHN • Leading in mCRC continuum of care RMS • Backbone therapy of choice with • Most prescribed HE oral in m

  31. Slide 31: Pimicotinib - phase III asset with 2024 readout

    Life Group Healthcare Electronics ESG Guidance Appendix Science Oncology Pimicotinib - phase III asset with 2024 readout Pimicotinib1 (Novel, highly selective and potent inhibitor of CSF-1R) Target indication: TGCT, a rare tumor of the joints that causes swelling, pain, stiffness; seriously affectin

  32. Slide 32: Regaining momentum in N&I innovation

    Life Group Healthcare Electronics ESG Guidance Appendix Science Innovative Franchises – R&D N&I Regaining momentum in N&I innovation, with careful risk control Cladribine capsules Enpatoran Immune reconstitution therapy Selective and potent dual TLR7/8 inhibitor High efficacy oral drug aiming at a “

  33. Slide 33: Oncology + External Innovation

    Life Group Healthcare Electronics ESG Guidance Appendix Science Innovative Franchises – R&D Oncology + External Innovation Executing early oncology strategy, with de-risked late-stage Pimicotinib Early- and mid- stage assets Highly selective and potent inhibitor of CSF-1R Including ATRi, PARPi, and

  34. Slide 34: Company pipeline

    Life Group Healthcare Electronics ESG Guidance Appendix Science Company pipeline December 15, 2024 Healthcare pipeline Phase 1 Phase 2 Phase 3 Registration pimicotinib (CSF-1R inhibitor) Study met the primary endpoint, Tenosynovial giant cell tumor (TGCT)1 open-label part ongoing avelumab (anti-PD-L

  35. Slide 35: Healthcare catalysts

    Life Group Healthcare Electronics ESG Guidance Appendix Science Healthcare catalysts Q1 2024 Q2 2024 Q3 2024 Q4 2024 Cladribine capsules (Immune Reconstitution Therapy) Study initiation - Phase III generalised Myasthenia Gravis Enpatoran Enpatoran (Oral TLR7/8 inhibitor ) (Oral TLR7/8 inhibitor ) Re

  36. Slide 36: Compounding growth faster as AI enabler

    Life Group Healthcare Electronics ESG Guidance Appendix Science Electronics Compounding growth faster as AI enabler with ecosystem relevance End Market Growth Positioned for Key Megatrends Leadership, Innovation and Growth Above market Reconfirming growth extended to Raising mid-term org. sales mid-

  37. Slide 37: Transformation complete: accelerating growth as pure-play

    Life Group Healthcare Electronics ESG Guidance Appendix Science Electronics Transformation complete: accelerating growth as a pure-play illustrative 5-9% growth1 3-6% growth 2-3% growth5 beyond mid-term FY13 FY21 FY23 Mid-term → 0% semis >60% semis >68% semis >80% semis Surface Solutions Display: Ge

  38. Slide 38: Megatrends drive demand for wafers, materials and equipment

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Megatrends drive demand for wafers, materials and equipment More applications cause …which requires more …driving wafer explosion in data… powerful chips… volume step up Sensors, MEMs, Memory chips4 : Devices DRA

  39. Slide 39: Critical enabler of the Semiconductor Ecosystem

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Company is a critical enabler of the Semiconductor Ecosystem Materials, Delivery Equipment and Metrology & Inspection enable key process steps Key high-value manufacturing processes Chip Prototyping & Testing Sub

  40. Slide 40: Creates more customer value per wafer

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Company creates more customer value per wafer 1) Miniaturization1: more 2) Vertical stacking creates 3) HI8 interconnect density and process steps2,3, more materials complexity5 and more value6 complexity drives

  41. Slide 41: Strategic partner to customers with comprehensive portfolio

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Strategic partner to customers with comprehensive portfolio Resilient business model with partial semi cycle hedge Strategic partner to industry Materials + Service Ramp-up Customer engagement at Projects (after

  42. Slide 42: Complexity and miniaturization needs driving growth areas

    Life Group Healthcare Electronics ESG Guidance Appendix Science Display3 Complexity and miniaturization needs driving growth areas Group to deploy Materials IntelligenceTM Semiconductor and light-based amid increasing complexity technologies converge into Optronics Silicon Extremely high accuracy Do

  43. Slide 43: Leveraging portfolio transition to enable 5% to 9% growth

    Life Group Healthcare Electronics ESG Guidance Appendix Science Leveraging portfolio transition to enable 5% to 9%9 growth CAGR 1 2 3 Sales split Mid-term outlook Business Split Fundamental growth drivers Semiconductor Materials ▪ Continued market growth due to technological advances that generate,

  44. Slide 44: Sustainable innovation drives future business growth

    Life Group Healthcare Electronics ESG Guidance Appendix Science Sustainable innovation drives future business growth Reducing the upstream footprint of products for customers More sustainable products Reducing impact with environmental Green Speed app quantifies impact for our customers progress, ah

  45. Slide 45: Three overall sustainability ambitions

    Life Group Healthcare Electronics ESG Guidance Appendix Science We are committed to three overall sustainability ambitions 01 Partnering for 02 03 Dedicated to Reducing our sustainable business human progress ecological footprint impact In 2030, we will achieve human progress By 2030, we will fully

  46. Slide 46: Clear metrics to drive progress towards 2030 ambition

    Life Group Healthcare Electronics ESG Guidance Appendix Science Clear Metrics to drive execution and progress towards 2030 ambition Goal Metric 2023 (2022) Target 1 Percentage of newly published patent families with positive sustainability impact 29% (40%1) n.a. People treated with our HC products*

  47. Slide 47: Diverse human capital

    Life Group Healthcare Electronics ESG Guidance Appendix Science Diverse human capital: Thinking, talking, and leading differently Indicator Status Focus areas Aspirations 2023 (2022) Gender parity Gender Percentage of women in leadership globally 39% (38%) until 2030 Percentage of underrepresented e

  48. Slide 48: Responsible use of natural resources

    Life Group Healthcare Electronics ESG Guidance Appendix Science Responsible use of natural resources Scope 1+2 GHG emissions: -50% 80% of purchased electricity from Circularity Rate4 of 70% kt absolute reduction by 20301,2,4 renewable sources by 2030 for the whole company 2152 1951 100% 80% 2,000 17

  49. Slide 49: Full-year 2024 guidance

    Life Group Healthcare Electronics ESG Guidance Appendix Science Group Full-year 2024 guidance Net sales: Organic: +2% to +5% YoY FX: -3% to 0% YoY ~€20.7 – €22.1 bn, trending in the lower half of the range EBITDA pre: Organic: +4% to +10% YoY FX: -5% to -1% YoY ~€5.8 – €6.4 bn, trending around the m

  50. Slide 50: 2024 business sector guidance

    Life Group Healthcare Electronics ESG Guidance Appendix Science 2024 business sector guidance1 Net sales EBITDA pre Life Science ▪ Organic: -2% to +2% YoY ▪ Organic:-6% to +1% YoY ▪ FX: -3% to +1% YoY ▪ FX: -4% to 0% YoY ▪ ~€8.80 bn to €9.50 bn, trending slightly above ▪ ~€2.55 bn to €2.80 bn, trend

  51. Slide 51: Additional financial guidance 2024

    Life Group Healthcare Electronics ESG Guidance Appendix Science Additional financial guidance 2024 Further financial details Corporate & Other EBITDA pre -€450 m to -€520 m3 Interest result2 ~ €-65 m to -95 m4 Effective tax rate ~ 21% to 23% Capex on PPE1 ~ €1.6 to 1.8 bn FY 2024 overall hedge ratio

  52. Slide 52: Stable dividend signals confidence in future growth

    Life Group Healthcare Electronics ESG Guidance Appendix Science Stable dividend signals confidence in future growth Dividend1 development 2016 - 2023 2023 dividend ▪ Resilient company performance supports stable dividend in FY23 2.20 2.20 ▪ Allows for dividend1 of €2.20 per share for 2023 1.85 2 ▪ D

  53. Slide 53: Credit details

    Life Group Healthcare Electronics ESG Guidance Appendix Science Credit details Maturity profile as of September 30, 2024 Credit rating information Coupon [€m / $m] 3.250% Last LT LT ST 0.125% Rating Outlook Rating Rating Change 1.625% 1.875% 3.875% 2.875% A3 21.10.21 Stable P-2 1,600 1.625% 3.375% 8

  54. Slide 54: Return to growth accelerates, driven by Healthcare and Electronics

    Life Group Healthcare Electronics ESG Guidance Appendix Science Return to growth accelerates, driven by Healthcare and Electronics 9M YoY Net Sales 9M YoY EBITDA pre Organic Currency Portfolio Total €4,586 m 3.3% €4,581 m Life Science -5.0% -0.9% 0.0% -6.0% -3.4% 0.0% Healthcare 7.1% -2.2% 0.0% 4.9%

  55. Slide 55: 9M 2024: Overview

    Life Group Healthcare Electronics ESG Guidance Appendix Science 9M 2024: Overview Key figures Comments [€m] 9M 2023 9M 2024 Δ ▪ Sales around stable with slight organic sales growth and FX headwinds Net sales 15,768 15,738 -0.2% ▪ Strong growth in Healthcare EBITDA pre EBITDA pre 4,586 4,581 -0.1% pa

  56. Slide 56: 9M 2024: Reported figures

    Life Group Healthcare Electronics ESG Guidance Appendix Science 9M 2024: Reported figures Reported results Comments ▪ EBIT declines, driven mainly by €140 m [€m] 9M 2023 9M 2024 Δ impairment of Xevinapant in Q2’24 and EBIT 2,988 2,821 -5.6% lower Life Science EBIT Financial result -144 -93 -35.2% ▪

  57. Slide 57: Cash flow statement

    Life Group Healthcare Electronics ESG Guidance Appendix Science Cash flow statement 9M 2024 – cash flow statement Cash flow drivers [€m] 9M 2023 9M 2024 Δ ▪ Profit after tax driven by lower EBIT Profit after tax 2,246 2,117 -129 ▪ D&A includes one-time impairments in D&A 1,373 1,583 210 relation to

  58. Slide 58: Adjustments in 9M 2024

    Life Group Healthcare Electronics ESG Guidance Appendix Science Adjustments in 9M 2024 Adjustments in EBIT [€m] 9M 2023 9M 2024 Adjustments thereof D&A Adjustments thereof D&A Life Science 76 32 124 56 Healthcare -30 -1 134 155 Electronics 67 19 54 13 Corporate & Other 162 0 89 1 Total 276 50 401 22

  59. Slide 59: Process Solutions - Market

    Life Group Healthcare Electronics ESG Guidance Appendix Science Process Solutions - Market Participating in a structurally intact and attractively growing Biopharma market Novels driving growth Diversified customer base Process products market in € bn By type, geography, modality mAbs, Vax, Plasma,

  60. Slide 60: Process Solutions – Innovation

    Life Group Healthcare Electronics ESG Guidance Appendix Science Process Solutions – Innovation Enabling customers’ transformation towards Factory of the Future Today Future Customer goals mAbs: Templated process Facility of the Future Innovation examples Novels: Need for template (mAbs leading, fina

  61. Slide 61: Life Science Services – Footprint

    Life Group Healthcare Electronics ESG Guidance Appendix Science Life Science Services – Footprint Global network with the ability to offer services across all stages of the molecules value chain Global footprint Service offering Overview of current network Overview of services across the molecules v

  62. Slide 62: Life Science Services – Overview

    Life Group Healthcare Electronics ESG Guidance Appendix Science Life Science Services – Overview Focus on novel modalities to provide unique value proposition to clients and propel future growth Capabilities Snapshot Serving customers along their molecule journey Business in numbers1 CDMO CTO Dev. D

  63. Slide 63: Life Science Services – Ambition

    Life Group Healthcare Electronics ESG Guidance Appendix Science Life Science Services – Ambition Existing business the foundation for growth, ambition based on technology leadership in novel modalities Short term Mid term Long term “Emerging novel modality “Full-service novel modality “Leading full-

  64. Slide 64: SLS – Portfolio

    Life Group Healthcare Electronics ESG Guidance Appendix Science SLS – Portfolio Broad portfolio consisting of five specialized portfolio units and franchises enabling a presence across workflows Chemistry Biology DxRm BioM Lab Water Full value chain offers across segments enabled by technology-centr

  65. Slide 65: SLS – Customers & Value Chains

    Life Group Healthcare Electronics ESG Guidance Appendix Science SLS – Customers & Value Chains Serving full value chains of diverse customer segments with key customers including global leaders in their fields Customer segments & value chains served Customer universe R&D Manufact. QA/QC Example cust

  66. Slide 66: SLS – Key Trends & Initiatives

    Life Group Healthcare Electronics ESG Guidance Appendix Science SLS – Key Trends & Initiatives Addressing key industry & macroeconomic trends with innovative solutions and targeted investments Industry trends Macroeconomic trends Secular trends Dual sourcing & Digitalization & Regulatory Sustainabil

  67. Slide 67: Process Solutions: Returning to growth

    Life Group Healthcare Electronics ESG Guidance Appendix Science Process Solutions: Returning to growth with highest sales for five quarters Sales development [€m] - org. growth [%] YoY 893 896 ▪ Org. sales rise with improving volumes on 873 871 higher activity levels; sales up 3% sequentially with a

  68. Slide 68: Science & Lab Solutions: Solid YoY growth

    Life Group Healthcare Electronics ESG Guidance Appendix Science Science & Lab Solutions: Solid YoY growth Sales development [€m] - org. growth [%] YoY 1,170 1,192 1,111 1,137 1,143 ▪ Solid sales growth year-over-year; excluding SAP migration impact from Q3’23, still slight sales growth ▪ Biomonitori

  69. Slide 69: Life Science Services: down against high comparable

    Life Group Healthcare Electronics ESG Guidance Appendix Science Life Science Services: down against high comparable Sales development [€m] - org. growth [%] YoY 220 ▪ Sales down against high comparable 206 194 ▪ Contract testing up high-single-digit percentage org. 171 ▪ CDMO down, with high compara

  70. Slide 70: Life Science 9M

    Life Group Healthcare Electronics ESG Guidance Appendix Science Life Science 9M: Gradual progression in Q3 improves YTD performance Life Science P&L Net sales bridge [€m] IFRS Pre €7,031 m 0.0% €6,611 m 9M 2023 9M 2024 9M 2023 9M 2024 -5.0% -0.9% Net sales 7,031 6,611 7,031 6,611 M&S -1,689 -1,661 -

  71. Slide 71: Healthcare: Solid growth in CM&E and Fertility

    Life Group Healthcare Electronics ESG Guidance Appendix Science Healthcare Solid growth in CM&E and Fertility, long-term growth led by innovation Mid-term growth drivers Global specialty • CM&E and Fertility portfolio as innovator resilient backbone leveraging regional diversification slight • Withi

  72. Slide 72: Key pillars of DDR strategy

    Life Group Healthcare Electronics ESG Guidance Appendix Science DNA damage response PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE Key pillars of DDR strategy: tuvusertib and M9466 Tuvusertib M9466 ATRi PARP1 Differentiate through optimized Differentiate through selection of tumors therapeutic window un

  73. Slide 73: Tuvusertib monotherapy profile

    Life Group Healthcare Electronics ESG Guidance Appendix Science DNA damage response PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE Tuvusertib monotherapy profile enables combination potential Achieves strong target coverage Compares favorably on safety % of time typical Tuvusertib Cav fold for pCHK1 pat

  74. Slide 74: M9466: next-gen PARP1i

    Life Group Healthcare Electronics ESG Guidance Appendix Science DNA damage response PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE M9466: next-gen PARP1i key to realizing combination potential M9466: 2nd gen PARP inhibitor with trapping activity Hengrui: Ph1 study of M9466/ HRS-1167 - PARylation inhibit

  75. Slide 75: ADC technology addresses limitations of first-gen ADCs

    Life Group Healthcare Electronics ESG Guidance Appendix Science Oncology - ADCs PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE Group's ADC technology addresses the limitations of first-gen ADCs First generation ADCs Group’s ADC Platform  Unfavorable target expression  Mono & bispecific internalizing A

  76. Slide 76: Precemtabart tocentecan (M9140) development program

    Life Group Healthcare Electronics ESG Guidance Appendix Science Oncology - ADCs PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE Precemtabart tocentecan (M9140): Developing First-in-Class ADC in CEACAM5-positive tumors First-in-human and expansion studies in CRC Precemtabart tocentecan CRC combinations Do

  77. Slide 77: Enhancing our position as a major ADC player

    Life Group Healthcare Electronics ESG Guidance Appendix Science Pre-clinical space PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE Enhancing our position as a major ADC player ADC priorities Organic ADC portfolio growth in the next 3 years ▪ Maximize exatecan platform M3554 (GD2) ▪ Embark into immune M91

  78. Slide 78: Enpatoran: targeted inhibition of lupus mediator

    Life Group Healthcare Electronics ESG Guidance Appendix Science N&I - Enpatoran PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE Targeted inhibition of important lupus mediator aiming for improved efficacy with low infection risk • For lupus patients, precise intervention for improved efficacy at low infe

  79. Slide 79: Enpatoran: expansion into myositis

    Life Group Healthcare Electronics ESG Guidance Appendix Science N&I - Enpatoran PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE Expansion into myositis, First-in-Class Potential Development Rationale Neptunia Study ▪ G7 prevalence of 100 – 120K ▪ Debilitating autoimmune disease, characterized by muscle w

  80. Slide 80: Cladribine – going beyond multiple sclerosis

    Life Group Healthcare Electronics ESG Guidance Appendix Science N&I - Cladribine PIMICOTINIB DDRs ADCs ENPATORAN CLADRIBINE Cladribine – going beyond multiple sclerosis s.c. Cladribine Open Label Study in MG Development Rationale ▪ Myasthenia gravis is a neuromuscular disease with high unmet need ▪

  81. Slide 81: Healthcare 9M

    Life Group Healthcare Electronics ESG Guidance Appendix Science Healthcare 9M: Strong first nine months supported across franchises Healthcare P&L Net sales bridge [€m] IFRS Pre €6,021 m 7.1% 0.0% €6,318 m -2.2% 9M 2023 9M 2024 9M 2023 9M 2024 Net sales 6,021 6,318 6,021 6,318 M&S -1,208 -1,251 -1,1

  82. Slide 82: Accelerating growth by enabling AI and advanced nodes

    Life Group Healthcare Electronics ESG Guidance Appendix Science Electronics Accelerating growth by enabling AI and advanced nodes Semiconductors Ecosystem CAGR of 7% to 11% driven by +200 to relevant portfolio 5 to 9%1 +400bps2 growth above MSI (5% to 7%) CAGR Display Around stable as growth areas b

  83. Slide 83: Tech roadmap needs more powerful chips

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Tech roadmap needs more powerful chips; powerful chips are driven by the ability to think (logic) and remember more (memory), faster Advanced logic needs more Simple miniaturization has limits, to Heterogeneous I

  84. Slide 84: Materials Intelligence & Metrology Tools

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Enabling tech roadmaps with Materials IntelligenceTM & Metrology Tools Miniaturization: reaching the Vertical stacking and complexity: Heterogenous Integration limitation of getting smaller precision at the atomi

  85. Slide 85: Enabling AI and advanced nodes

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Enabling AI and adv. nodes, outgrowing the wider Semi market AI segment outpaces the AI at the Edge will be the Faster growth in adv. nodes2,3, semiconductor market1 bigger opportunity where Group is prominent AI

  86. Slide 86: AI-driven complexity makes yield more challenging

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions AI-driven complexity makes yield even more challenging Increasing cost per chip1 Falling yields3 AI adds complexity4 2x max size (move to 3rd chip) ~15% CAGR 834mm2 max chip Chip 1 Chip 2 size Chip area (mm2) Pro

  87. Slide 87: Strategic partner to semiconductor manufacturers

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions MATERIALS DS&S R&D Services Metrology Strategic Partner to semiconductor manufacturers globally 2 Fab1 material market 4 Semiconductor +4.9% Materials Winning in the fab1 with process owners 22E 23E 24E 06 19 04

  88. Slide 88: Comprehensive materials portfolio

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions MATERIALS DS&S R&D Services Metrology Comprehensive materials portfolio across all relevant technologies Advanced materials mission Broad technology families required for current and future critical to wafer proc

  89. Slide 89: Safe and reliable delivery of hazardous materials

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Materials DS&S R&D Services Metrology Trusted player in safe and reliable delivery of hazardous materials Highly synergistic business model providing partial hedge to semiconductor cycle Gas & chemical MEGASYS &

  90. Slide 90: Innovation pipeline aligned to tech roadmap

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Materials DS&S R&D SERVICES Metrology Innovation pipeline aligned to tech roadmap enables future growth Innovation focus on winning new Attractive pipeline of semi materials and Process of Records with annuity in

  91. Slide 91: Advanced metrology and inspection tools

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions Materials DS&S R&D Services METROLOGY Advanced metrology and inspection tools enable two key megatrends 1. Heterogenous Integration for AI & Advanced Nodes New advanced 3D optical metrology is key AI Accelerator

  92. Slide 92: Perfectly positioned as integrated player

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions MATERIALS DS&S R&D SERVICES METROLOGY Company perfectly positioned as integrated player Electronics has four transformational Integrated Segment Players3 Integrated Ecosystem Player4 layers of integration Comp C

  93. Slide 93: Semiconductor Solutions recovery pace tempers

    Life Group Healthcare Electronics ESG Guidance Appendix Science Semiconductor Solutions recovery pace tempers in the near-term Sales development [€m] - org. growth [%] YoY 660 665 633 642 ▪ Overall, continued strong org. sales 612 growth in Semiconductor Solutions ▪ Semi Materials with substantial Y

  94. Slide 94: Electronics 9M

    Life Group Healthcare Electronics ESG Guidance Appendix Science Electronics 9M: Strong Semiconductor Solutions growth Electronics P&L Net sales bridge [€m] IFRS Pre €2,716 m 5.4% €2,809 m -1.8% -0.2% 9M 2023 9M 2024 9M 2023 9M 2024 Net sales 2,716 2,809 2,716 2,809 M&S -450 -420 -447 -420 9M 2023 Or

  95. Slide 95: Company's ownership structure

    Life Group Healthcare Electronics ESG Guidance Appendix Science Company‘s ownership structure Shareholders E. Merck KG, Darmstadt, Germany: of Merck KGaA , Darmstadt, Germany Partners‘ Meeting & Family Board ▪ Shareholders hold ~30% of Company’s total capital ▪ E. Merck KG, Darmstadt, Germany KG (99

  96. Slide 96: Long-Term Incentive Plan

    Life Group Healthcare Electronics ESG Guidance Appendix Science Pay for performance reflecting the company’s long-term strategy Long-Term Incentive Merck Long-Term Plan Plan Incentive ▪ Reflecting the long-term strategy for Company’s growth and (from 2022) sustainability ambition Performance of Grou

  97. Slide 97: Executive Board incentive linked to sustainability

    Life Group Healthcare Electronics ESG Guidance Appendix Science Executive Board long-term incentive linked to sustainability ▪ Since fiscal year 2022, our sustainability strategy will be even more firmly embedded in the compensation system for the members of the Executive Board ▪ The sustainability

  98. Slide 98: Reduce our environmental footprint

    Life Group Healthcare Electronics ESG Guidance Appendix Science Reduce our environmental footprint: Emissions, Water and Waste Goal Climate neutrality Enhance water Reduce waste 3 by 2040 efficiency & purity impact ▪ Lower scope 1+2 GHG3 ▪ Enhancing water efficiency: ▪ Until 2030, we aim to emission

  99. Slide 99: External stakeholders assess our engagement

    Life Group Healthcare Electronics ESG Guidance Appendix Science External stakeholders assess our engagement Since 2022, Company is Company received a Since 2008, Company is part In the ISS corporate ESG1 receiving a MSCI ESG1 Sustainalytics ESG1 Risk of FTSE4Good Index, ranking Company achieved Rati

  100. Slide 100: Meet the team

    FLORIAN SCHRAEDER NADJA GROSSCHMIDT SUSAN KUEHN eet the team Head of Investor Relations Assistant Investor Relations Assistant Investor Relations +49 6151 72-5271 +49 6151 72-3321 +49 6151 72-3744 [email protected] [email protected] [email protected] DATE EVENT March

Merck KGaA, Darmstadt, Germany — Non-Deal Roadshow (January 2025) on 6ix